How we got from “mental restlessness“ to modern ADHD
ADHD is sometimes painted as a 21st-century invention. It isn't. The condition has been described in the medical literature for over 200 years. Here is the timeline that took us from “a defect of attention“ to today's neuroscience.
1798 — Alexander Crichton (Scotland)
Scottish physician Sir Alexander Crichton publishes 'An Inquiry into the Nature and Origin of Mental Derangement', containing the first detailed clinical description of what he called 'mental restlessness' — incapacity of attending with consistency, distractibility, and the inability to sustain effort. Almost every modern criterion is in there.
1902 — George Still's Royal College lectures
British paediatrician Sir George Still gives a series of lectures to the Royal College of Physicians describing 43 children with 'an abnormal defect of moral control'. He noted it ran in families, occurred more in boys, and wasn't caused by bad parenting.
1922–1937 — encephalitis and 'minimal brain damage'
After the 1918 encephalitis epidemic, doctors saw similar symptoms emerge in survivors and coined 'post-encephalitic behaviour disorder' — leading later to the 'minimal brain dysfunction' label of the 1950s and 60s.
1937 — first stimulant trial (Bradley)
Charles Bradley, a Rhode Island paediatrician, gives Benzedrine to children with behaviour problems and notes a remarkable calming, focusing effect. The result is largely ignored for 25 years.
1968 — DSM-II names it
The American Psychiatric Association adds 'Hyperkinetic Reaction of Childhood' to the DSM-II — the first formal diagnostic category.
1980 — DSM-III: “ADD“
The DSM-III renames it Attention Deficit Disorder, with or without hyperactivity — finally acknowledging that attention, not just hyperactivity, is the core problem.
1987–1994 — “ADHD“ as we know it
DSM-III-R (1987) coins ADHD. DSM-IV (1994) defines the three subtypes — inattentive, hyperactive, combined — still in use today.
1990s — the brain-imaging era
fMRI and PET studies confirm measurable differences in prefrontal cortex, basal ganglia and dopamine receptor density in ADHD brains. ADHD is officially a neurological condition, not a behavioural choice.
1999 — the MTA study
The Multimodal Treatment of ADHD study (USA, 579 children) is the largest ever — and finds combined medication + behavioural therapy outperforms either alone, with stimulants being more effective than community care.
2008 — NICE clinical guideline 72
The UK's first national ADHD guideline (later updated to NG87) formally adopts stimulant treatment for children and adults, and recognises adult ADHD as a distinct condition.
2013 — DSM-5: adult criteria
DSM-5 formally allows ADHD diagnosis at any age, lowers the symptom threshold for adults, and removes the autism exclusion — finally acknowledging AuDHD.
2020s — the diagnosis surge
Diagnoses (especially in women and adults) rise sharply post-pandemic — not because the condition is new, but because remote work, social media awareness, and improved clinical training have closed a recognition gap.